About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Patient-Led Decisions Accelerate IBD Treatment Switching, Spherix Global Insights Finds

By: via GlobeNewswire

EXTON, PA, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Patients with inflammatory bowel disease (IBD) in the US are taking a more active role than ever before in the decision to switch their advanced therapies, driving faster transitions between treatments and creating opportunities for brand growth, according to Spherix Global Insights’ newly published Patient Chart Dynamix™: Switching in IBD (US) service.

An analysis of approximately 1,000 IBD patient charts submitted by 200 gastroenterologists, each capturing a biologic, JAK inhibitor, or S1P receptor modulator switch within the past three months, reveals a marked rise since 2017 in the proportion of switches driven significantly or primarily by patients in both ulcerative colitis (UC) and Crohn’s disease (CD). In most patient-led switches captured in the 2025 audit, individuals were clinically informed about their disease status. Importantly, when patients played a significant role in initiating a switch, the average time spent on their previous agent was considerably shorter compared to cases where they played a lesser role.

This shift in decision-making comes at a time of unprecedented change in the IBD market. In the past three years, multiple new therapies have entered the space, prompting updated treatment guidelines from leading societies including the American Gastroenterological Association (AGA) and the American College of Gastroenterology (ACG). With competition intensifying across biologics, JAK inhibitors, and S1P receptor modulators, brands are emphasizing distinct features to stand out, including Johnson & Johnson Innovative Medicines’ Tremfya subcutaneous induction in CD and AbbVie’s Skyrizi On-Body Injector.

As patients play a greater role in treatment decisions, manufacturers have an opportunity to shape these conversations. Educational initiatives that equip patients to recognize inadequate disease control and engage proactively with physicians can reduce time to switching, speed brand uptake, and drive better outcomes.

Spherix will continue to closely monitor these and other trends in IBD. Additionally, the European counterpart to this analysis, Patient Chart Dynamix™: Switching in IBD (EU5), will be released in the coming months, offering additional insights into regional differences and the evolving role of patients in treatment decision-making.

About Patient Chart Dynamix™

Patient Chart Dynamix™ is an independent service that includes robust patient chart audits and integrated specialist surveys fielded biannually. This research provides an in-depth, real-world view of treatment practices by combining verified patient data with attitudinal insights from physicians. The series highlights clinical decision-making, treatment sequencing, and outcomes for targeted patient populations across key therapeutic areas.

About Spherix Global Insights   

Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle.   

The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community.   

As a trusted advisor and industry thought leader, Spherix’s unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth.   

To learn more about Spherix Global Insights, visit spherixglobalinsights.com or connect through LinkedIn.   

For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here: https://clientportal.spherixglobalinsights.com    

NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and analysis addressed within are based on Spherix Global Insight’s analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release.


Jim Hickey, Gastroenterology Franchise Head
Spherix Global Insights
4848794284
james.hickey@spherixglobalinsights.com

More News

View More
These 3 Crypto Stocks Could Get a Bump as Dollar Trust Weakens
Via MarketBeat
Topics ETFs Economy World Trade
Tickers BITF COIN HOOD
T-Mobile's CEO: Why Market Jitters Create a Buying Opportunity
Via MarketBeat
Tickers TMUS
MarketBeat Week in Review – 09/22 - 09/26
Via MarketBeat
Topics Economy
Tickers AMPX AVGO CRWD DVLT EVTL GME
Pfizer is Locking in New Growth Through a New Acquisition
Via MarketBeat
Topics Artificial Intelligence
Tickers MTSR PFE
Copper Giant Freeport Slumps but Analysts See 33% Upside
Via MarketBeat
Tickers FCX SCCO
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.